Free Trial

Mereo BioPharma Group (MREO) News Today

Mereo BioPharma Group logo
$2.38 -0.17 (-6.47%)
As of 02:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group plc (NASDAQ:MREO) Given Average Rating of "Buy" by Brokerages
Mereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are presently covering the company, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and two have issued a strong buy reco
Mereo BioPharma Group plc stock logo
Acuta Capital Partners LLC Sells 481,392 Shares of Mereo BioPharma Group plc (NASDAQ:MREO)
Acuta Capital Partners LLC reduced its holdings in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 38.2% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 779,308 shares of the company's stock after selling 481,
Mereo BioPharma Group plc stock logo
683 Capital Management LLC Trims Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO)
683 Capital Management LLC cut its holdings in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,550,000 shares of the company's
Mereo BioPharma Group plc stock logo
Marshall Wace LLP Lowers Stake in Mereo BioPharma Group plc (NASDAQ:MREO)
Marshall Wace LLP cut its stake in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 15.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 866,317 shares of the company's stock after selling 162,195 shares during
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group plc (NASDAQ:MREO) Stock Position Lowered by Adage Capital Partners GP L.L.C.
Adage Capital Partners GP L.L.C. lowered its position in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 10.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,715,013 shares of the comp
Mereo BioPharma Group plc stock logo
Blue Owl Capital Holdings LP Trims Stock Holdings in Mereo BioPharma Group plc (NASDAQ:MREO)
Blue Owl Capital Holdings LP lessened its stake in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 20.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 672,809 shares of the company's stock after selling 175,000
Mereo BioPharma Group plc stock logo
Walleye Capital LLC Makes New Investment in Mereo BioPharma Group plc (NASDAQ:MREO)
Walleye Capital LLC bought a new stake in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 129,629 shares of the company's stock, valued at approximately $454,000. Wall
Mereo BioPharma Group plc stock logo
Renaissance Technologies LLC Sells 115,900 Shares of Mereo BioPharma Group plc (NASDAQ:MREO)
Renaissance Technologies LLC lowered its stake in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 8.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,189,471 shares of the company's stock after selling 115,900 shares during the quarter. Renaissan
Mereo BioPharma Group plc (MREO): A Bull Case Theory
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group plc (NASDAQ:MREO) Given Average Recommendation of "Buy" by Brokerages
Mereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) has received an average rating of "Buy" from the eight analysts that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group (NASDAQ:MREO) Given "Buy" Rating at Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a research note on Wednesday.
Mereo BioPharma Group plc stock logo
Cantor Fitzgerald Forecasts MREO FY2025 Earnings
Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Mereo BioPharma Group in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska forecasts that the company will post earnings of ($0.08)
Mereo BioPharma Group plc stock logo
Research Analysts Offer Predictions for MREO Q1 Earnings
Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Mereo BioPharma Group in a research note issued on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz expects that the company will earn $0.07 per share for the quarter
Mereo BioPharma Group plc stock logo
JPMorgan Chase & Co. Begins Coverage on Mereo BioPharma Group (NASDAQ:MREO)
JPMorgan Chase & Co. initiated coverage on Mereo BioPharma Group in a report on Thursday. They set an "overweight" rating and a $7.00 price target on the stock.
Mereo BioPharma initiated with an Overweight at JPMorgan
Cantor Fitzgerald Remains a Buy on Mereo Biopharma Group Plc (MREO)
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group's (MREO) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research note on Wednesday.
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group (NASDAQ:MREO) Releases Earnings Results, Misses Estimates By $0.03 EPS
Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.03).
Mereo BioPharma sees cash runway into 2027
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group (NASDAQ:MREO) Receives Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reissued an "overweight" rating and set a $7.00 target price on shares of Mereo BioPharma Group in a report on Tuesday.
Mereo BioPharma Group plc stock logo
Tejara Capital Ltd Reduces Stock Position in Mereo BioPharma Group plc (NASDAQ:MREO)
Tejara Capital Ltd decreased its position in shares of Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 18.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,317,085 shares of the company's stock after selling 5
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group (MREO) to Release Quarterly Earnings on Wednesday
Mereo BioPharma Group (NASDAQ:MREO) will be releasing earnings before the market opens on Wednesday, March 26, Financial Modeling Prep reports.
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group plc (NASDAQ:MREO) Receives Consensus Rating of "Buy" from Brokerages
Mereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) has been given a consensus recommendation of "Buy" by the seven ratings firms that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and three have given a strong buy recommend
Mereo BioPharma management to meet with Cantor Fitzgerald
Background of different dollar banknotes — Stock Editorial Photography
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential (MREO)
Uncover five promising stocks under $10, each poised for gains across diverse sectors for the second quarter of 2025.
Mereo BioPharma Group plc stock logo
HealthInvest Partners AB Has $1.37 Million Stock Position in Mereo BioPharma Group plc (NASDAQ:MREO)
HealthInvest Partners AB lifted its position in Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) by 95.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 390,000 shares of the co
Mereo BioPharma: Good Science, Fairly Valued
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group plc (NASDAQ:MREO) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Mereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) have been given an average rating of "Buy" by the seven analysts that are covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy rating and three have given a strong buy rating to
Mereo BioPharma Group plc stock logo
Cantor Fitzgerald Comments on MREO FY2024 Earnings
Mereo BioPharma Group plc (NASDAQ:MREO - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Mereo BioPharma Group in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings of ($0
BTIG Sticks to Its Buy Rating for Mereo Biopharma Group Plc (MREO)
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group (NASDAQ:MREO) Sets New 52-Week Low - Here's Why
Mereo BioPharma Group (NASDAQ:MREO) Sets New 52-Week Low - Here's Why
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group (NASDAQ:MREO) Shares Gap Down - What's Next?
Mereo BioPharma Group (NASDAQ:MREO) Shares Gap Down - What's Next?
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group (NASDAQ:MREO) Receives "Buy" Rating from Needham & Company LLC
Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a report on Monday.
Mereo BioPharma Provides Update on Lead Clinical Programs
Mereo BioPharma Group plc stock logo
Mereo BioPharma Group plc (NASDAQ:MREO) Receives Average Recommendation of "Buy" from Brokerages
Shares of Mereo BioPharma Group plc (NASDAQ:MREO - Get Free Report) have received an average rating of "Buy" from the seven brokerages that are currently covering the company, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and three have issued a strong buy recomm
Get Mereo BioPharma Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.

MREO Media Mentions By Week

MREO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MREO
News Sentiment

1.39

0.69

Average
Medical
News Sentiment

MREO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MREO Articles
This Week

3

2

MREO Articles
Average Week

Get Mereo BioPharma Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:MREO) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners